PubMed Health⌕ Search

Biomedical subjects

J U Barrie

Publications and source records attributed to J U Barrie.

11 recordsLinked to original sources
PubMed1987

Occult fetomaternal haemorrhage as a cause of fetal mortality and morbidity.

Spontaneous fetomaternal haemorrhage is an important, but usually overlooked, cause of perinatal mortality and morbidity. Although fetomaternal bleeding in the third trimester of pregnancy is common it is normally less than 0.1 ml. A fetal macrotransfusion (greater than 5 ml) is uncommon, but is important because it is insidious, unexpected and usually occurs in completely normal pregnancies. This paper analyses the perinatal mortality and morbidity associated with occult fetomaternal haemorrhage at the Royal Women's Hospital, Melbourne. It may lead to fetal distress before and during labour, unexplained stillbirth, or nonhaemolytic neonatal anaemia. A Kleihauer test on maternal blood will readily detect fetomaternal bleeding, and we describe a simple way of calculating the absolute volume of fetal red cells present. Greater awareness of the problem may eventually lead to diagnosis sufficiently early to permit effective treatment.

Adult↗
PubMed1979

The relation between maternal serum alpha-fetoprotein levels and fetomaternal haemorrhage.

Spontaneous fetomaternal haemorrhage at 14 to 20 weeks gestation resulted in raised serum alpha-fetoprotein (AFP) levels in 13 of 150 patients attending a genetic counselling clinic. In all 13 patients, the placenta was anterior or fundal in position. By allowing for a rise in serum AFP levels of 4 microgram/l for each fetal cell seen in 30 high power fields (Kleihauer test), a 62.5 per cent reduction in the number of patients selected for amniocentesis because of raised serum AFP levels would have been achieved. The occurrence of fetomaternal haemorrhages at the time of amniocentesis can be detected by either the Kleihauer technique or the measurement of maternal serum AFP levels.

Adult↗
PubMed1977

Anti-D prophylaxis.

Explore the source record for details and available documents.

Extraction, Obstetrical↗
PubMed1977

Significance of red-cell irregular antibodies in the obstetric patient.

Irregular antibodies were identified in 1.3% of obstetric patients who were delivered at the Royal women's Hospital, Melbourne. The most common antibodies found were anti-P1 and anti-Lewis, but, although these antibodies may cause difficulty in obtaining compatible blood if transfusion is required, they were not associated with haemolytic disease of the newborn. Immunization with other irregular antibodies, especially Rhesus subtype and Kell, may occur due to pregnancy alone or follow the combination of pregnancy and incompatible blood transfusion. Irrespective of the initial cause of immunization, these antibodies are often associated with haemolytic disease of the newborn which may be severe enough to result in perinatal death. As most irregular antibodies are found in patients with Rh-positive blood, the need for screening of all antenatal patients in each pregnancy must be recognized.

Blood Transfusion↗
PubMed1976

Cellular immunity to lymphocyte antigens in human infertility.

The leukocyte migration test was used to detect cellular immunity to HL-A antigens present on the husband's lymphocytes and spermatozoa in a group of fertile and infertile couples. Approximately 50% of the married female population appear to be sensitized. There was no difference between the fertile and infertile groups in the frequency of positive results, but a greater number of migration indices were below 0.7 and 0.6 in the infertile group. It is suggested that sperm cells are the most likely cause of immunization.

Cell Migration Inhibition↗
PubMed1975

Return of spermatogenesis after stopping cyclophosphamide therapy.

A follow-up of twenty-six male patients with azoospermia after stopping cyclophosphamide treatment showed a return of spermatogenesis in twelve patients within 15-49 months (mean 31 months). In one patient spermatogenesis returned despite 34 months of treatment with 100 mg. of cyclophosphamide daily. The period of follow-up after stopping cyclophosphamide therapy varied from 5 months to 4 years. After 6 months on cyclophosphamide all patients remained azoospermic while taking the drug. Return of spermatogenesis was not significantly associated with age, duration of cyclophosphamide therapy, total dose, or time of follow-up after stopping treatment; however, the number of patients in the study was small.

Adult↗